Back to Search Start Over

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration

Authors :
Bjorn Gudbjornsson
Tore K Kvien
Marco Sebastiani
Mikkel Østergaard
Anne Gitte Loft
Stylianos Georgiadis
Maria José Santos
Anna-Mari Hokkanen
Gary J. Macfarlane
Manuel Pombo-Suarez
Jenny Österlund
Catalin Codreanu
Fatos Onen
Servet Akar
Johan Askling
Lykke Midtbøll Ørnbjerg
Arni Jon Geirsson
Ruxandra Ionescu
Matija Tomšič
Brigitte Michelsen
Ziga Rotar
Carlos Sánchez-Piedra
Irene E. van der Horst-Bruinsma
Joseph O. Sexton
Ulf Lindström
Merete Lund Hetland
Florenzo Iannone
Helena Santos
Karel Pavelka
Michael John Nissen
Cecilie Heegaard Brahe
Jakub Zavada
Adrian Ciurea
Læknadeild (HÍ)
Faculty of Medicine (UI)
Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Háskóli Íslands
University of Iceland
Rheumatology
AII - Inflammatory diseases
Amsterdam Movement Sciences
AMS - Tissue Function & Regeneration
Repositório da Universidade de Lisboa
HUS Internal Medicine and Rehabilitation
Source :
Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, RMD Open, 6(3). BMJ Publishing Group, RMD Open, Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A-M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, ' Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration ', RMD Open, vol. 6, no. 3 . https://doi.org/10.1136/rmdopen-2020-001280, Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, ' Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration ', RMD Open, vol. 6, no. 3 . https://doi.org/10.1136/rmdopen-2020-001280, Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, ' Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration ', RMD Open, vol. 6, no. 3, e001280 . https://doi.org/10.1136/rmdopen-2020-001280
Publication Year :
2020
Publisher :
BMJ Publishing Group Ltd, 2020.

Abstract

Publisher's version (útgefin grein)<br />OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)<br />The EuroSpA collaboration was financially supported by Novartis. Novartishad no influence on the data collection, statistical analyses, manuscript preparationor decision to submit. The national registries have received financial support froma range of pharmaceutical companies, including Novartis. These funds are given asunrestricted grants

Details

Language :
English
ISSN :
20565933
Database :
OpenAIRE
Journal :
Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, RMD Open, 6(3). BMJ Publishing Group, RMD Open, Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A-M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, ' Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration ', RMD Open, vol. 6, no. 3 . https://doi.org/10.1136/rmdopen-2020-001280, Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, ' Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration ', RMD Open, vol. 6, no. 3 . https://doi.org/10.1136/rmdopen-2020-001280, Michelsen, B, Lindström, U, Codreanu, C, Ciurea, A, Zavada, J, Loft, A G, Pombo-Suarez, M, Onen, F, Kvien, T K, Rotar, Z, Santos, M J, Iannone, F, Hokkanen, A M, Gudbjornsson, B, Askling, J, Ionescu, R, Nissen, M J, Pavelka, K, Sanchez-Piedra, C, Akar, S, Sexton, J, Tomsic, M, Santos, H, Sebastiani, M, Österlund, J, Geirsson, A J, Macfarlane, G, van der Horst-Bruinsma, I, Georgiadis, S, Brahe, C H, Ørnbjerg, L M, Hetland, M L & Østergaard, M 2020, ' Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment : routine care data from 13 registries in the EuroSpA collaboration ', RMD Open, vol. 6, no. 3, e001280 . https://doi.org/10.1136/rmdopen-2020-001280
Accession number :
edsair.doi.dedup.....978ccb19c28c7f1cd3383e9237ca59cb